Navigation Links
K-V Pharmaceutical Company Receives Notification From New York Stock Exchange of Compliance With Quantitative Continued Listing Standards
Date:9/2/2010

ts sold by the Company or its subsidiaries including without limitation the litigation and claims referred to in Note 18 - "Commitments and Contingencies" of the Notes to the Consolidated Financial Statements in the Form 10-Q, and that any adverse judgments or settlements of such litigation, including product liability lawsuits, may be material to the Company;
  • the possibility that our current estimates of the financial effect of certain announced product recalls could prove to be incorrect;
  • whether any product recalls or product introductions result in litigation, agency action or material damages;
  • failure to supply claims by certain of the Company's customers, including CVS Pharmacy, Inc., that, despite the formal discontinuation action by the Company of its products, the Company should compensate such customers for any additional costs they allegedly incurred for procuring products the Company did not supply;
  • the satisfaction or waiver of the terms and conditions for the acquisition of the full U.S. and worldwide rights to Gestiva™ set forth in the previously disclosed Gestiva™ acquisition agreement, as amended;
  • the series of putative class action lawsuits alleging violations of the federal securities laws by the Company and certain individuals, as more fully described in Note 18 - "Commitments and Contingencies - Litigation and Governmental Inquiries" of the Notes to the Consolidated Financial Statements in the Form 10-Q;
  • the possibility that insurance proceeds are insufficient to cover potential losses that may arise from litigation, including with respect to product liability, failure to supply or securities litigation;
  • the informal inquiry initiated by the SEC and any related or additional government investigation or enforcement proceedings as more fully described in Note 18 - "Commitments and Contingencies - Litigation and Government Inquiries, of the Notes to the Consolidated Financial State
    '/>"/>

  • SOURCE K-V Pharmaceutical Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
    2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
    9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... MOUNTAIN VIEW, Calif. , July 24, 2014 ... ), a leading provider of medication and supply ... hold a conference call Thursday, July 31, to ... What:  , Omnicell Second Quarter 2014 earnings ... 2014, 1:30 p.m. PTWho:  , Randall Lipps, chairman, ...
    (Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... "the company") announced today that the company,s board of directors ... 31 to June 30. Accordingly, DelMar will file a Transition ... Jeffrey Bacha , president and CEO of DelMar stated, ... in achieving our goal of obtaining a senior exchange listing ...
    (Date:7/24/2014)... 24, 2014 LSI Medience Corporation today ... with Kineticos, a Raleigh-Durham, NC ... support LSI Medience in identifying opportunities for Presepsin, ... utility in clinical trials. The Presepsin ... diagnosis of sepsis, prognosis of septic patients, early ...
    Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2
    ... Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that ... 2012 at 8:30 a.m. Eastern Time to provide an update ... Inc., a member of the Roche Group (SIX: RO, ROG; ... (888) 660-6127 International Dial-in Number: (973) 890-8355 Participant Code:  40392582 ...
    ... SINGAPORE, Dec. 30, 2011 /PRNewswire-Asia/ -- Biosensors International Group, ... SGX: B20), a developer, manufacturer and marketer of innovative ... today announced it will be participating in the 30th ... from 9th to 12th January 2012 in San Francisco, ...
    Cached Medicine Technology:Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation 2Biosensors International to Participate in the 30th Annual J.P. Morgan Healthcare Conference 2
    (Date:7/25/2014)... July 25, 2014 Eye & Vision ... at their office location by expanding a new specialized ... kind comprehensive visual electro-physiology clinic. , By acquiring specialized ... of experience in vision problems, patients with vision loss ... take advantage of the implementation of this specialized vision ...
    (Date:7/25/2014)... 2014 The European liquid chromatography reagents ... with analysis and forecast of revenue. The liquid chromatography ... million in 2013, and is estimated to grow to ... 9.4 %, from 2013 to 2018. , Browse through ... to get an idea of the in-depth analysis provided. ...
    (Date:7/25/2014)... genes may play a greater role in language delay ... Researchers found more evidence that language traits, such ... inherited. The study involving 473 sets of twins ... language performance for twins than single-born children) was greater ... disputes hypotheses that attribute delays in early language acquisition ...
    (Date:7/25/2014)... are switched on or off plays a key role ... UT Southwestern Medical Center researchers have found., The research ... and diabetes, since the transcription factor involved spliced ... the body,s sensitivity to insulin and leptin signaling. Insulin ... of food intake and sugar disposal, and obesity and ...
    (Date:7/25/2014)... The American Brain Tumor Association (ABTA) announced today ... Distinguished Events, and Corporate and Special Events Manager - ... be joining the ABTA in the newly created position ... roll out of a nationwide brain tumor volunteer effort ... volunteer network will provide the Chicago-based ABTA with a ...
    Breaking Medicine News(10 mins):Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 2Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Genes May Be Key to Language Delay in Kids 2Health News:Manipulating key protein in the brain holds potential against obesity and diabetes 2Health News:American Brain Tumor Association Recruits Director to Lead New Volunteer Network 2
    ... and efficacy of first FDA-approved nebulized ... COPD -, NAPA, Calif., May 16 Dey, ... given at the International,Conference of the American Thoracic Society ... Center. One of the presentations details the,effects on dyspnea ...
    ... mastectomy (total breast removal) for early-stage breast cancer has ... in Rochester. The increase follows a steady decline during ... for this increase are unclear. But they have determined ... resonance imaging (MRI) prior to surgery to treat early-stage ...
    ... sooner if therapy is working , , FRIDAY, May 16 ... levels of circulating tumor cells can help doctors more ... with metastatic breast cancer, according to a Georgetown University ... weeks, and sometimes months, to determine if a particular ...
    ... /Xinhua-PRNewswire-FirstCall/ --,Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ... distributor,of high-quality, pharmaceutical grade glucose products in China, ... March 31, 2008., Third Quarter of ... to $20.7 million -- Gross profit rose ...
    ... May 16 IDM Pharma, Inc.,(Nasdaq: IDMI ... Company,s lead product candidates will be made at ... annual meeting. Data presented,at the meeting will support ... L-MTP-PE, as well as patients with non-small lung,cancer ...
    ... wake of divorce, illness, violence and other problems that ... experience temporary separations from one or both parents before ... May/June issue of Ambulatory Pediatrics, a new, community-wide study ... at increased risk for learning difficulties and that these ...
    Cached Medicine News:Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 2Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 3Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 4Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 5Health News: Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers 2Health News: Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers 3Health News:Blood Test Helps Docs Assess Breast Cancer Treatment 2Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 2Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 3Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 4Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 5Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 6Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 7Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 8Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 9Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 10Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 11Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 12Health News:IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting 2Health News:IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting 3Health News:Separation from mom, dad linked with learning trouble in kids 2Health News:Separation from mom, dad linked with learning trouble in kids 3
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: